June 30, 2022

Dr. Matthew Dallimore Appointed President of Radiation Monitoring Devices, Inc.

Dynasil Corporation of America is pleased to announce the appointment of Dr. Matthew Dallimore as President of Radiation Monitoring Devices, Inc. (“RMD”).

“Dr. Dallimore brings a wealth of knowledge and expertise in the fields of science where RMD is a recognized world leader,” said Peter Sulick, President and CEO of Dynasil. “We believe his expertise will be instrumental in continuing to successfully move RMD forward.”

January 7, 2021

Dynasil Appoints Militram Futuristic Technologies to Target Israel’s Fast Growing Industrial, Commercial and Military Segments

Dynasil Corporation of America ("Dynasil" or the "Company"), a leading developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for homeland security, medical and industrial markets, today announces that it has appointed Militram Futuristic Technologies of Israel to pursue the growing demand in Israel’s industrial, commercial and military segments.

February 4, 2020

Dynasil-Innovative Solutions for Leading-Edge Applications in Photonics

Printed in Photonics News Daily

Dynasil, a global supplier of fused silica, coatings, components, and scintillation and detection solutions, is focused on cutting-edge research and commercial product development in photonics. With eight locations across two continents, it serves customers in more than 60 countries. CEO Peter Sulick shares operational highlights and what lies ahead for the industry and Dynasil.

May 17, 2018

Dynasil Appoints Nirmal Parikh, VP of Marketing

Dynasil Corporation of America ("Dynasil" or the "Company") (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the appointment of Nirmal Parikh, a 20-year industry expert to the position of Vice President, Marketing.

February 22, 2018

DYSL Annual 2018 Meeting Management Presentation

Presentation given at the Dynasil Corporation of America Annual Meeting on February 22, 2018. Presenation by Peter Sulick, CEO and Chairman Dynasil Corporation, Linda Zuckerman Ph.D. CEO Xcede Technologies, Kanai Shah Ph.D., President RMD, and Gary Bishop Ph.D. V.P. of Photonics Dynasil Corporation.

January 17, 2018

Dynasil Corporation of America Enters Infrared High Efficiency and DLC Coatings Market

Newton, Mass., January 17, 2018 – Dynasil Corporation of America (NASDAQ: DYSL) today announced its subsidiaries EMF Corporation and Optometrics Corporation have completed their development of the first in a series of Infrared High Efficiency Anti-Reflective (HEAR) thin film coatings for the eight to twelve micron spectral region.

January 11, 2018

Dynasil Announces Submission of Xcede Technologies’ Application for First-in- Human Clinical Trial

Newton, MA. Jan 11, 2018 – The Xcede Patch clinical trial dossier was submitted today to the Medical Ethical Review Committee (MREC) Universitair Medisch Centrum Groningen (Netherlands), in anticipation of a first-in-human clinical trial. The clinical trial, which outlines the treatment of up to 30 patients undergoing various types of liver resection, will take place at two major liver surgery centers in The Netherlands. Subject to the MREC approvals, the Company anticipates that patients will be treated with the Xcede Patch in the Netherlands in early 2018.

February 28, 2017

Dynasil Hosts Annual Meeting

Dynasil hosted its annual meeting on February 23rd, 2017 in Watertown, MA on the campus of its RMD subsidiary. The meeting included presentations by President and CEO, Peter Sulick, President of RMD, Dr. Kanai Shah and CEO of Xcede, Dr. Linda Zuckerman.

February 13, 2017

Dynasil Corporation of America Reports First Quarter Fiscal 2017 Recognition of Deferred Tax Asset Benefit of $2.7 million

Newton, MA, February 13, 2017 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced earnings attributable to common stockholders of $2.8 million or $0.17 per common share for the first quarter of the 2017 fiscal year, largely as the result of a U.S. income tax benefit resulting from the deconsolidation for tax purposes of Xcede Technologies, Inc., the Company’s tissue sealant technology development joint venture.